

Global Bacterial Vaginosis Drug Market Analysis and Forecast 2024-2030

<https://marketpublishers.com/r/G39779518F3DEN.html>

Date: April 2024

Pages: 200

Price: US\$ 4,950.00 (Single User License)

ID: G39779518F3DEN

Abstracts

Summary

This report studies the Bacterial Vaginosis Drug market, Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria. This report includes metronidazole, clindamycin drug and other drugs.

According to APO Research, The global Bacterial Vaginosis Drug market is projected to grow from US\$ million in 2024 to US\$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Bacterial Vaginosis Drug is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Bacterial Vaginosis Drug is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Bacterial Vaginosis Drug is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Bacterial Vaginosis Drug is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global companies of Bacterial Vaginosis Drug include Bayer, Pfizer, Sanofi, Piramal, Abbott, Galderma, Mission, Alkem and Xiuzheng, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Bacterial Vaginosis Drug, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Bacterial Vaginosis Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Bacterial Vaginosis Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Bacterial Vaginosis Drug revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Bacterial Vaginosis Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Bacterial Vaginosis Drug revenue, projected growth trends, production technology, application and end-user industry.

Bacterial Vaginosis Drug segment by Company

Bayer

Pfizer

Sanofi

Piramal

Abbott

Galderma

Mission

Alkem

Xiuzheng

Teva

Perrigo

West-Ward

HPGC

Yunnan Baiyao

Starpharma

Novel

Edenridge

Bacterial Vaginosis Drug segment by Type

Rx

OTC

Bacterial Vaginosis Drug segment by Application

Hospital

Pharmacy

Other

Bacterial Vaginosis Drug segment by Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product

launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bacterial Vaginosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bacterial Vaginosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bacterial Vaginosis Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Bacterial Vaginosis Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Bacterial Vaginosis Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Bacterial Vaginosis Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

Contents

1 MARKET OVERVIEW

- 1.1 Product Definition
- 1.2 Bacterial Vaginosis Drug Market by Type
 - 1.2.1 Global Bacterial Vaginosis Drug Market Size by Type, 2019 VS 2023 VS 2030
 - 1.2.2 Rx
 - 1.2.3 OTC
- 1.3 Bacterial Vaginosis Drug Market by Application
 - 1.3.1 Global Bacterial Vaginosis Drug Market Size by Application, 2019 VS 2023 VS 2030
 - 1.3.2 Hospital
 - 1.3.3 Pharmacy
 - 1.3.4 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives

2 BACTERIAL VAGINOSIS DRUG MARKET DYNAMICS

- 2.1 Bacterial Vaginosis Drug Industry Trends
- 2.2 Bacterial Vaginosis Drug Industry Drivers
- 2.3 Bacterial Vaginosis Drug Industry Opportunities and Challenges
- 2.4 Bacterial Vaginosis Drug Industry Restraints

3 GLOBAL GROWTH PERSPECTIVE

- 3.1 Global Bacterial Vaginosis Drug Market Perspective (2019-2030)
- 3.2 Global Bacterial Vaginosis Drug Growth Trends by Region
 - 3.2.1 Global Bacterial Vaginosis Drug Market Size by Region: 2019 VS 2023 VS 2030
 - 3.2.2 Global Bacterial Vaginosis Drug Market Size by Region (2019-2024)
 - 3.2.3 Global Bacterial Vaginosis Drug Market Size by Region (2025-2030)

4 COMPETITIVE LANDSCAPE BY PLAYERS

- 4.1 Global Bacterial Vaginosis Drug Revenue by Players
 - 4.1.1 Global Bacterial Vaginosis Drug Revenue by Players (2019-2024)
 - 4.1.2 Global Bacterial Vaginosis Drug Revenue Market Share by Players (2019-2024)
 - 4.1.3 Global Bacterial Vaginosis Drug Players Revenue Share Top 10 and Top 5 in

2023

4.2 Global Bacterial Vaginosis Drug Key Players Ranking, 2022 VS 2023 VS 2024

4.3 Global Bacterial Vaginosis Drug Key Players Headquarters & Area Served

4.4 Global Bacterial Vaginosis Drug Players, Product Type & Application

4.5 Global Bacterial Vaginosis Drug Players Commercialization Time

4.6 Market Competitive Analysis

4.6.1 Global Bacterial Vaginosis Drug Market CR5 and HHI

4.6.2 Global Top 5 and 10 Bacterial Vaginosis Drug Players Market Share by Revenue in 2023

4.6.3 2023 Bacterial Vaginosis Drug Tier 1, Tier 2, and Tier

5 BACTERIAL VAGINOSIS DRUG MARKET SIZE BY TYPE

5.1 Global Bacterial Vaginosis Drug Revenue by Type (2019 VS 2023 VS 2030)

5.2 Global Bacterial Vaginosis Drug Revenue by Type (2019-2030)

5.3 Global Bacterial Vaginosis Drug Revenue Market Share by Type (2019-2030)

6 BACTERIAL VAGINOSIS DRUG MARKET SIZE BY APPLICATION

6.1 Global Bacterial Vaginosis Drug Revenue by Application (2019 VS 2023 VS 2030)

6.2 Global Bacterial Vaginosis Drug Revenue by Application (2019-2030)

6.3 Global Bacterial Vaginosis Drug Revenue Market Share by Application (2019-2030)

7 COMPANY PROFILES

7.1 Bayer

7.1.1 Bayer Company Information

7.1.2 Bayer Business Overview

7.1.3 Bayer Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)

7.1.4 Bayer Bacterial Vaginosis Drug Product Portfolio

7.1.5 Bayer Recent Developments

7.2 Pfizer

7.2.1 Pfizer Company Information

7.2.2 Pfizer Business Overview

7.2.3 Pfizer Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)

7.2.4 Pfizer Bacterial Vaginosis Drug Product Portfolio

7.2.5 Pfizer Recent Developments

7.3 Sanofi

7.3.1 Sanofi Company Information

- 7.3.2 Sanofi Business Overview
- 7.3.3 Sanofi Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
- 7.3.4 Sanofi Bacterial Vaginosis Drug Product Portfolio
- 7.3.5 Sanofi Recent Developments
- 7.4 Piramal
 - 7.4.1 Piramal Company Information
 - 7.4.2 Piramal Business Overview
 - 7.4.3 Piramal Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
 - 7.4.4 Piramal Bacterial Vaginosis Drug Product Portfolio
 - 7.4.5 Piramal Recent Developments
- 7.5 Abbott
 - 7.5.1 Abbott Company Information
 - 7.5.2 Abbott Business Overview
 - 7.5.3 Abbott Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
 - 7.5.4 Abbott Bacterial Vaginosis Drug Product Portfolio
 - 7.5.5 Abbott Recent Developments
- 7.6 Galderma
 - 7.6.1 Galderma Company Information
 - 7.6.2 Galderma Business Overview
 - 7.6.3 Galderma Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
 - 7.6.4 Galderma Bacterial Vaginosis Drug Product Portfolio
 - 7.6.5 Galderma Recent Developments
- 7.7 Mission
 - 7.7.1 Mission Company Information
 - 7.7.2 Mission Business Overview
 - 7.7.3 Mission Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
 - 7.7.4 Mission Bacterial Vaginosis Drug Product Portfolio
 - 7.7.5 Mission Recent Developments
- 7.8 Alkem
 - 7.8.1 Alkem Company Information
 - 7.8.2 Alkem Business Overview
 - 7.8.3 Alkem Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
 - 7.8.4 Alkem Bacterial Vaginosis Drug Product Portfolio
 - 7.8.5 Alkem Recent Developments
- 7.9 Xiuzheng
 - 7.9.1 Xiuzheng Company Information
 - 7.9.2 Xiuzheng Business Overview
 - 7.9.3 Xiuzheng Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
 - 7.9.4 Xiuzheng Bacterial Vaginosis Drug Product Portfolio

- 7.9.5 Xiuzheng Recent Developments
- 7.10 Teva
 - 7.10.1 Teva Company Information
 - 7.10.2 Teva Business Overview
 - 7.10.3 Teva Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
 - 7.10.4 Teva Bacterial Vaginosis Drug Product Portfolio
 - 7.10.5 Teva Recent Developments
- 7.11 Perrigo
 - 7.11.1 Perrigo Company Information
 - 7.11.2 Perrigo Business Overview
 - 7.11.3 Perrigo Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
 - 7.11.4 Perrigo Bacterial Vaginosis Drug Product Portfolio
 - 7.11.5 Perrigo Recent Developments
- 7.12 West-Ward
 - 7.12.1 West-Ward Company Information
 - 7.12.2 West-Ward Business Overview
 - 7.12.3 West-Ward Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
 - 7.12.4 West-Ward Bacterial Vaginosis Drug Product Portfolio
 - 7.12.5 West-Ward Recent Developments
- 7.13 HPGC
 - 7.13.1 HPGC Company Information
 - 7.13.2 HPGC Business Overview
 - 7.13.3 HPGC Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
 - 7.13.4 HPGC Bacterial Vaginosis Drug Product Portfolio
 - 7.13.5 HPGC Recent Developments
- 7.14 Yunnan Baiyao
 - 7.14.1 Yunnan Baiyao Company Information
 - 7.14.2 Yunnan Baiyao Business Overview
 - 7.14.3 Yunnan Baiyao Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
 - 7.14.4 Yunnan Baiyao Bacterial Vaginosis Drug Product Portfolio
 - 7.14.5 Yunnan Baiyao Recent Developments
- 7.15 Starpharma
 - 7.15.1 Starpharma Company Information
 - 7.15.2 Starpharma Business Overview
 - 7.15.3 Starpharma Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
 - 7.15.4 Starpharma Bacterial Vaginosis Drug Product Portfolio
 - 7.15.5 Starpharma Recent Developments
- 7.16 Novel

- 7.16.1 Novel Comapny Information
- 7.16.2 Novel Business Overview
- 7.16.3 Novel Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
- 7.16.4 Novel Bacterial Vaginosis Drug Product Portfolio
- 7.16.5 Novel Recent Developments
- 7.17 Edenvridge
 - 7.17.1 Edenvridge Comapny Information
 - 7.17.2 Edenvridge Business Overview
 - 7.17.3 Edenvridge Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
 - 7.17.4 Edenvridge Bacterial Vaginosis Drug Product Portfolio
 - 7.17.5 Edenvridge Recent Developments

8 NORTH AMERICA

- 8.1 North America Bacterial Vaginosis Drug Revenue (2019-2030)
- 8.2 North America Bacterial Vaginosis Drug Revenue by Type (2019-2030)
 - 8.2.1 North America Bacterial Vaginosis Drug Revenue by Type (2019-2024)
 - 8.2.2 North America Bacterial Vaginosis Drug Revenue by Type (2025-2030)
- 8.3 North America Bacterial Vaginosis Drug Revenue Share by Type (2019-2030)
- 8.4 North America Bacterial Vaginosis Drug Revenue by Application (2019-2030)
 - 8.4.1 North America Bacterial Vaginosis Drug Revenue by Application (2019-2024)
 - 8.4.2 North America Bacterial Vaginosis Drug Revenue by Application (2025-2030)
- 8.5 North America Bacterial Vaginosis Drug Revenue Share by Application (2019-2030)
- 8.6 North America Bacterial Vaginosis Drug Revenue by Country
 - 8.6.1 North America Bacterial Vaginosis Drug Revenue by Country (2019 VS 2023 VS 2030)
 - 8.6.2 North America Bacterial Vaginosis Drug Revenue by Country (2019-2024)
 - 8.6.3 North America Bacterial Vaginosis Drug Revenue by Country (2025-2030)
 - 8.6.4 U.S.
 - 8.6.5 Canada

9 EUROPE

- 9.1 Europe Bacterial Vaginosis Drug Revenue (2019-2030)
- 9.2 Europe Bacterial Vaginosis Drug Revenue by Type (2019-2030)
 - 9.2.1 Europe Bacterial Vaginosis Drug Revenue by Type (2019-2024)
 - 9.2.2 Europe Bacterial Vaginosis Drug Revenue by Type (2025-2030)
- 9.3 Europe Bacterial Vaginosis Drug Revenue Share by Type (2019-2030)
- 9.4 Europe Bacterial Vaginosis Drug Revenue by Application (2019-2030)

- 9.4.1 Europe Bacterial Vaginosis Drug Revenue by Application (2019-2024)
- 9.4.2 Europe Bacterial Vaginosis Drug Revenue by Application (2025-2030)
- 9.5 Europe Bacterial Vaginosis Drug Revenue Share by Application (2019-2030)
- 9.6 Europe Bacterial Vaginosis Drug Revenue by Country
 - 9.6.1 Europe Bacterial Vaginosis Drug Revenue by Country (2019 VS 2023 VS 2030)
 - 9.6.2 Europe Bacterial Vaginosis Drug Revenue by Country (2019-2024)
 - 9.6.3 Europe Bacterial Vaginosis Drug Revenue by Country (2025-2030)
 - 9.6.4 Germany
 - 9.6.5 France
 - 9.6.6 U.K.
 - 9.6.7 Italy
 - 9.6.8 Russia

10 CHINA

- 10.1 China Bacterial Vaginosis Drug Revenue (2019-2030)
- 10.2 China Bacterial Vaginosis Drug Revenue by Type (2019-2030)
 - 10.2.1 China Bacterial Vaginosis Drug Revenue by Type (2019-2024)
 - 10.2.2 China Bacterial Vaginosis Drug Revenue by Type (2025-2030)
- 10.3 China Bacterial Vaginosis Drug Revenue Share by Type (2019-2030)
- 10.4 China Bacterial Vaginosis Drug Revenue by Application (2019-2030)
 - 10.4.1 China Bacterial Vaginosis Drug Revenue by Application (2019-2024)
 - 10.4.2 China Bacterial Vaginosis Drug Revenue by Application (2025-2030)
- 10.5 China Bacterial Vaginosis Drug Revenue Share by Application (2019-2030)

11 ASIA (EXCLUDING CHINA)

- 11.1 Asia Bacterial Vaginosis Drug Revenue (2019-2030)
- 11.2 Asia Bacterial Vaginosis Drug Revenue by Type (2019-2030)
 - 11.2.1 Asia Bacterial Vaginosis Drug Revenue by Type (2019-2024)
 - 11.2.2 Asia Bacterial Vaginosis Drug Revenue by Type (2025-2030)
- 11.3 Asia Bacterial Vaginosis Drug Revenue Share by Type (2019-2030)
- 11.4 Asia Bacterial Vaginosis Drug Revenue by Application (2019-2030)
 - 11.4.1 Asia Bacterial Vaginosis Drug Revenue by Application (2019-2024)
 - 11.4.2 Asia Bacterial Vaginosis Drug Revenue by Application (2025-2030)
- 11.5 Asia Bacterial Vaginosis Drug Revenue Share by Application (2019-2030)
- 11.6 Asia Bacterial Vaginosis Drug Revenue by Country
 - 11.6.1 Asia Bacterial Vaginosis Drug Revenue by Country (2019 VS 2023 VS 2030)
 - 11.6.2 Asia Bacterial Vaginosis Drug Revenue by Country (2019-2024)

11.6.3 Asia Bacterial Vaginosis Drug Revenue by Country (2025-2030)

11.6.4 Japan

11.6.5 South Korea

11.6.6 India

11.6.7 Australia

11.6.8 China Taiwan

11.6.9 Southeast Asia

12 MIDDLE EAST, AFRICA, LATIN AMERICA

12.1 MEALA Bacterial Vaginosis Drug Revenue (2019-2030)

12.2 MEALA Bacterial Vaginosis Drug Revenue by Type (2019-2030)

12.2.1 MEALA Bacterial Vaginosis Drug Revenue by Type (2019-2024)

12.2.2 MEALA Bacterial Vaginosis Drug Revenue by Type (2025-2030)

12.3 MEALA Bacterial Vaginosis Drug Revenue Share by Type (2019-2030)

12.4 MEALA Bacterial Vaginosis Drug Revenue by Application (2019-2030)

12.4.1 MEALA Bacterial Vaginosis Drug Revenue by Application (2019-2024)

12.4.2 MEALA Bacterial Vaginosis Drug Revenue by Application (2025-2030)

12.5 MEALA Bacterial Vaginosis Drug Revenue Share by Application (2019-2030)

12.6 MEALA Bacterial Vaginosis Drug Revenue by Country

12.6.1 MEALA Bacterial Vaginosis Drug Revenue by Country (2019 VS 2023 VS 2030)

12.6.2 MEALA Bacterial Vaginosis Drug Revenue by Country (2019-2024)

12.6.3 MEALA Bacterial Vaginosis Drug Revenue by Country (2025-2030)

12.6.4 Mexico

12.6.5 Brazil

12.6.6 Israel

12.6.7 Argentina

12.6.8 Colombia

12.6.9 Turkey

12.6.10 Saudi Arabia

12.6.11 UAE

13 CONCLUDING INSIGHTS

14 APPENDIX

14.1 Reasons for Doing This Study

14.2 Research Methodology

- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
 - 14.5.1 Secondary Sources
 - 14.5.2 Primary Sources
- 14.6 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Bacterial Vaginosis Drug Market Size Growth Rate by Type (US\$ Million), 2019 VS 2023 VS 2030

Table 1. Rx Major Manufacturers

Table 2. OTC Major Manufacturers

Table 3. Global Bacterial Vaginosis Drug Market Size Growth Rate by Application (US\$ Million), 2019 VS 2023 VS 2030

Table 4. Hospital Major Manufacturers

Table 5. Pharmacy Major Manufacturers

Table 6. Other Major Manufacturers

Table 7. Bacterial Vaginosis Drug Industry Trends

Table 8. Bacterial Vaginosis Drug Industry Drivers

Table 9. Bacterial Vaginosis Drug Industry Opportunities and Challenges

Table 10. Bacterial Vaginosis Drug Industry Restraints

Table 11. Global Bacterial Vaginosis Drug Market Size Growth Rate (CAGR) by Region (US\$ Million): 2019 VS 2023 VS 2030

Table 12. Global Bacterial Vaginosis Drug Market Size by Region (2019-2024) & (US\$ Million)

Table 13. Global Bacterial Vaginosis Drug Market Share by Region (2019-2024)

Table 14. Global Bacterial Vaginosis Drug Market Size by Region (2025-2030) & (US\$ Million)

Table 15. Global Bacterial Vaginosis Drug Market Share by Region (2025-2030)

Table 16. Global Bacterial Vaginosis Drug Revenue by Players (US\$ Million) & (2019-2024)

Table 17. Global Bacterial Vaginosis Drug Revenue Market Share by Players (2019-2024)

Table 18. Global Bacterial Vaginosis Drug Key Players Ranking, 2022 VS 2023 VS 2024

Table 19. Global Bacterial Vaginosis Drug Key Players Headquarters & Area Served

Table 20. Global Bacterial Vaginosis Drug Players, Product Type & Application

Table 21. Global Bacterial Vaginosis Drug Players Commercialization Time

Table 22. Global Players Market Concentration Ratio (CR5 and HHI)

Table 23. Global Bacterial Vaginosis Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)

Table 24. Global Bacterial Vaginosis Drug Revenue by Type 2019 VS 2023 VS 2030 (US\$ Million)

Table 25. Global Bacterial Vaginosis Drug Revenue by Type (2019-2024) & (US\$ Million)

Table 26. Global Bacterial Vaginosis Drug Revenue by Type (2025-2030) & (US\$ Million)

Table 27. Global Bacterial Vaginosis Drug Revenue Market Share by Type (2019-2024) & (US\$ Million)

Table 28. Global Bacterial Vaginosis Drug Revenue Market Share by Type (2025-2030) & (US\$ Million)

Table 29. Global Bacterial Vaginosis Drug Revenue by Application 2019 VS 2023 VS 2030 (US\$ Million)

Table 30. Global Bacterial Vaginosis Drug Revenue by Application (2019-2024) & (US\$ Million)

Table 31. Global Bacterial Vaginosis Drug Revenue by Application (2025-2030) & (US\$ Million)

Table 32. Global Bacterial Vaginosis Drug Revenue Market Share by Application (2019-2024) & (US\$ Million)

Table 33. Global Bacterial Vaginosis Drug Revenue Market Share by Application (2025-2030) & (US\$ Million)

Table 34. Bayer Company Information

Table 35. Bayer Business Overview

Table 36. Bayer Bacterial Vaginosis Drug Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 37. Bayer Bacterial Vaginosis Drug Product Portfolio

Table 38. Bayer Recent Development

Table 39. Pfizer Company Information

Table 40. Pfizer Business Overview

Table 41. Pfizer Bacterial Vaginosis Drug Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 42. Pfizer Bacterial Vaginosis Drug Product Portfolio

Table 43. Pfizer Recent Development

Table 44. Sanofi Company Information

Table 45. Sanofi Business Overview

Table 46. Sanofi Bacterial Vaginosis Drug Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 47. Sanofi Bacterial Vaginosis Drug Product Portfolio

Table 48. Sanofi Recent Development

Table 49. Piramal Company Information

Table 50. Piramal Business Overview

Table 51. Piramal Bacterial Vaginosis Drug Revenue and Gross Margin (US\$ Million) &

(2019-2024)

Table 52. Piramal Bacterial Vaginosis Drug Product Portfolio

Table 53. Piramal Recent Development

Table 54. Abbott Company Information

Table 55. Abbott Business Overview

Table 56. Abbott Bacterial Vaginosis Drug Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 57. Abbott Bacterial Vaginosis Drug Product Portfolio

Table 58. Abbott Recent Development

Table 59. Galderma Company Information

Table 60. Galderma Business Overview

Table 61. Galderma Bacterial Vaginosis Drug Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 62. Galderma Bacterial Vaginosis Drug Product Portfolio

Table 63. Galderma Recent Development

Table 64. Mission Company Information

Table 65. Mission Business Overview

Table 66. Mission Bacterial Vaginosis Drug Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 67. Mission Bacterial Vaginosis Drug Product Portfolio

Table 68. Mission Recent Development

Table 69. Alkem Company Information

Table 70. Alkem Business Overview

Table 71. Alkem Bacterial Vaginosis Drug Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 72. Alkem Bacterial Vaginosis Drug Product Portfolio

Table 73. Alkem Recent Development

Table 74. Xiuzheng Company Information

Table 75. Xiuzheng Business Overview

Table 76. Xiuzheng Bacterial Vaginosis Drug Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 77. Xiuzheng Bacterial Vaginosis Drug Product Portfolio

Table 78. Xiuzheng Recent Development

Table 79. Teva Company Information

Table 80. Teva Business Overview

Table 81. Teva Bacterial Vaginosis Drug Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 82. Teva Bacterial Vaginosis Drug Product Portfolio

Table 83. Teva Recent Development

Table 84. Perrigo Company Information

Table 85. Perrigo Business Overview

Table 86. Perrigo Bacterial Vaginosis Drug Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 87. Perrigo Bacterial Vaginosis Drug Product Portfolio

Table 88. Perrigo Recent Development

Table 89. West-Ward Company Information

Table 90. West-Ward Business Overview

Table 91. West-Ward Bacterial Vaginosis Drug Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 92. West-Ward Bacterial Vaginosis Drug Product Portfolio

Table 93. West-Ward Recent Development

Table 94. HPGC Company Information

Table 95. HPGC Business Overview

Table 96. HPGC Bacterial Vaginosis Drug Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 97. HPGC Bacterial Vaginosis Drug Product Portfolio

Table 98. HPGC Recent Development

Table 99. Yunnan Baiyao Company Information

Table 100. Yunnan Baiyao Business Overview

Table 101. Yunnan Baiyao Bacterial Vaginosis Drug Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 102. Yunnan Baiyao Bacterial Vaginosis Drug Product Portfolio

Table 103. Yunnan Baiyao Recent Development

Table 104. Starpharma Company Information

Table 105. Starpharma Business Overview

Table 106. Starpharma Bacterial Vaginosis Drug Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 107. Starpharma Bacterial Vaginosis Drug Product Portfolio

Table 108. Starpharma Recent Development

Table 109. Novel Company Information

Table 110. Novel Business Overview

Table 111. Novel Bacterial Vaginosis Drug Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 112. Novel Bacterial Vaginosis Drug Product Portfolio

Table 113. Novel Recent Development

Table 114. Edenridge Company Information

Table 115. Edenridge Business Overview

Table 116. Edenridge Bacterial Vaginosis Drug Sales (K MT), Revenue (US\$ Million),

Price (USD/MT) and Gross Margin (2019-2024)

Table 117. Edenridge Bacterial Vaginosis Drug Product Portfolio

Table 118. Edenridge Recent Development

Table 119. North America Bacterial Vaginosis Drug Revenue by Type (2019-2024) & (US\$ Million)

Table 120. North America Bacterial Vaginosis Drug Revenue by Application (2019-2024) & (US\$ Million)

Table 121. North America Bacterial Vaginosis Drug Revenue by Country (2019 VS 2023 VS 2030) & (US\$ Million)

Table 122. North America Bacterial Vaginosis Drug Revenue by Country (2019-2024) & (US\$ Million)

Table 123. North America Bacterial Vaginosis Drug Revenue by Country (2025-2030) & (US\$ Million)

Table 124. Europe Bacterial Vaginosis Drug Revenue by Type (2019-2024) & (US\$ Million)

Table 125. Europe Bacterial Vaginosis Drug Revenue by Application (2019-2024) & (US\$ Million)

Table 126. Europe Bacterial Vaginosis Drug Revenue by Country (2019 VS 2023 VS 2030) & (US\$ Million)

Table 127. Europe Bacterial Vaginosis Drug Revenue by Country (2019-2024) & (US\$ Million)

Table 128. Europe Bacterial Vaginosis Drug Revenue by Country (2025-2030) & (US\$ Million)

Table 129. China Bacterial Vaginosis Drug Revenue by Type (2019-2024) & (US\$ Million)

Table 130. China Bacterial Vaginosis Drug Revenue by Application (2019-2024) & (US\$ Million)

Table 131. Asia Bacterial Vaginosis Drug Revenue by Type (2019-2024) & (US\$ Million)

Table 132. Asia Bacterial Vaginosis Drug Revenue by Application (2019-2024) & (US\$ Million)

Table 133. Asia Bacterial Vaginosis Drug Revenue by Country (2019 VS 2023 VS 2030) & (US\$ Million)

Table 134. Asia Bacterial Vaginosis Drug Revenue by Country (2019-2024) & (US\$ Million)

Table 135. Asia Bacterial Vaginosis Drug Revenue by Country (2025-2030) & (US\$ Million)

Table 136. MEALA Bacterial Vaginosis Drug Revenue by Type (2019-2024) & (US\$ Million)

Table 137. MEALA Bacterial Vaginosis Drug Revenue by Application (2019-2024) &

(US\$ Million)

Table 138. MEALA Bacterial Vaginosis Drug Revenue by Country (2019 VS 2023 VS 2030) & (US\$ Million)

Table 139. MEALA Bacterial Vaginosis Drug Revenue by Country (2019-2024) & (US\$ Million)

Table 140. MEALA Bacterial Vaginosis Drug Revenue by Country (2025-2030) & (US\$ Million)

Table 141. Research Programs/Design for This Report

Table 142. Authors List of This Report

Table 143. Secondary Sources

Table 144. Primary Sources

List Of Figures

LIST OF FIGURES

- Figure 1. Bacterial Vaginosis Drug Product Picture
- Figure 2. Global Bacterial Vaginosis Drug Market Size Growth Rate by Type (US\$ Million), 2019 VS 2023 VS 2030
- Figure 3. Global Bacterial Vaginosis Drug Market Size Share 2019 VS 2023 VS 2030
- Figure 4. Rx Picture
- Figure 5. OTC Picture
- Figure 6. Global Bacterial Vaginosis Drug Market Size Growth Rate by Application (US\$ Million), 2019 VS 2023 VS 2030
- Figure 7. Global Bacterial Vaginosis Drug Market Size Share 2019 VS 2023 VS 2030
- Figure 8. Hospital Picture
- Figure 9. Pharmacy Picture
- Figure 10. Other Picture
- Figure 11. Global Bacterial Vaginosis Drug Market Size (US\$ Million) & (2019-2030)
- Figure 12. Global Bacterial Vaginosis Drug Market Size, (US\$ Million), 2019 VS 2023 VS 2030
- Figure 13. Global Bacterial Vaginosis Drug Market Share by Region: 2019 VS 2023 VS 2030
- Figure 14. Global Bacterial Vaginosis Drug Players Revenue Share Top 10 and Top 5 in 2023
- Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
- Figure 16. Global Bacterial Vaginosis Drug Revenue by Type (2019 VS 2023 VS 2030) & (US\$ Million)
- Figure 17. Global Bacterial Vaginosis Drug Revenue Market Share 2019 VS 2023 VS 2030
- Figure 18. Global Bacterial Vaginosis Drug Revenue Market Share by Type (2019-2030)
- Figure 19. Global Bacterial Vaginosis Drug Revenue by Application (2019 VS 2023 VS 2030) & (US\$ Million)
- Figure 20. Global Bacterial Vaginosis Drug Revenue Market Share by Application (2019 VS 2023 VS 2030)
- Figure 21. Global Bacterial Vaginosis Drug Revenue Market Share by Application (2019-2030)
- Figure 22. North America Bacterial Vaginosis Drug Revenue YoY Growth (2019-2030) & (US\$ Million)
- Figure 23. North America Bacterial Vaginosis Drug Revenue by Type (2025-2030) &

(US\$ Million)

Figure 24. North America Bacterial Vaginosis Drug Revenue Share by Type (2019-2030)

Figure 25. North America Bacterial Vaginosis Drug Revenue by Application (2025-2030) & (US\$ Million)

Figure 26. North America Bacterial Vaginosis Drug Revenue Share by Application (2019-2030)

Figure 27. North America Bacterial Vaginosis Drug Revenue Share by Country (2019-2030)

Figure 28. United States Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 29. Canada Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 30. Europe Bacterial Vaginosis Drug Revenue YoY Growth (2019-2030) & (US\$ Million)

Figure 31. Europe Bacterial Vaginosis Drug Revenue by Type (2025-2030) & (US\$ Million)

Figure 32. Europe Bacterial Vaginosis Drug Revenue Share by Type (2019-2030)

Figure 33. Europe Bacterial Vaginosis Drug Revenue by Application (2025-2030) & (US\$ Million)

Figure 34. Europe Bacterial Vaginosis Drug Revenue Share by Application (2019-2030)

Figure 35. Europe Bacterial Vaginosis Drug Revenue Share by Country (2019-2030)

Figure 36. Germany Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 37. France Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 38. U.K. Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 39. Italy Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 40. Russia Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 41. Nordic Countries Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 42. China Bacterial Vaginosis Drug Revenue YoY Growth (2019-2030) & (US\$ Million)

Figure 43. China Bacterial Vaginosis Drug Revenue by Type (2025-2030) & (US\$ Million)

Figure 44. China Bacterial Vaginosis Drug Revenue Share by Type (2019-2030)

Figure 45. China Bacterial Vaginosis Drug Revenue by Application (2025-2030) & (US\$ Million)

Figure 46. China Bacterial Vaginosis Drug Revenue Share by Application (2019-2030)

Figure 47. Asia Bacterial Vaginosis Drug Revenue YoY Growth (2019-2030) & (US\$ Million)

Figure 48. Asia Bacterial Vaginosis Drug Revenue by Type (2025-2030) & (US\$ Million)

Figure 49. Asia Bacterial Vaginosis Drug Revenue Share by Type (2019-2030)

Figure 50. Asia Bacterial Vaginosis Drug Revenue by Application (2025-2030) & (US\$ Million)

Figure 51. Asia Bacterial Vaginosis Drug Revenue Share by Application (2019-2030)

Figure 52. Asia Bacterial Vaginosis Drug Revenue Share by Country (2019-2030)

Figure 53. Japan Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 54. South Korea Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 55. India Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 56. Australia Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 57. China Taiwan Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 58. Southeast Asia Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 59. MEALA Bacterial Vaginosis Drug Revenue YoY Growth (2019-2030) & (US\$ Million)

Figure 60. MEALA Bacterial Vaginosis Drug Revenue by Type (2025-2030) & (US\$ Million)

Figure 61. MEALA Bacterial Vaginosis Drug Revenue Share by Type (2019-2030)

Figure 62. MEALA Bacterial Vaginosis Drug Revenue by Application (2025-2030) & (US\$ Million)

Figure 63. MEALA Bacterial Vaginosis Drug Revenue Share by Application (2019-2030)

Figure 64. MEALA Bacterial Vaginosis Drug Revenue Share by Country (2019-2030)

Figure 65. Mexico Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 66. South Korea Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 67. Brazil Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 68. Israel Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) &

(2019-2030)

Figure 69. Argentina Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 70. Colombia Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 71. Turkey Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 72. Saudi Arabia Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 73. UAE Bacterial Vaginosis Drug Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 74. Years Considered

Figure 75. Research Process

Figure 76. Key Executives Interviewed

I would like to order

Product name: Global Bacterial Vaginosis Drug Market Analysis and Forecast 2024-2030

Product link: <https://marketpublishers.com/r/G39779518F3DEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G39779518F3DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970